Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Diagnosis
1213 results:
1. ReHoGCNES-MDA: prediction of miRNA-disease associations using homogenous graph convolutional networks based on regular graph with random edge sampler.
Zhang Y; Chu Y; Lin S; Xiong Y; Wei DQ
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38517693
[TBL] [Abstract] [Full Text] [Related]
2. Association between 19 medication use and risk of common cancers: A cross-sectional and Mendelian randomisation study.
Yun Z; Shen Y; Yan X; Tian S; Wang J; Teo CS; Zhao H; Xue C; Dong Q; Hou L
J Glob Health; 2024 Mar; 14():04057. PubMed ID: 38487860
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict prostate cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract] [Full Text] [Related]
5. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
6. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract] [Full Text] [Related]
7. Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer.
Zhang C; Gao X; Fan B; Guo S; Lyu X; Shi J; Fu Y; Zhang Q; Liu P; Guo H
World J Urol; 2024 Feb; 42(1):93. PubMed ID: 38386116
[TBL] [Abstract] [Full Text] [Related]
8. Smoking, Drinking, and Dietary Risk Factors for Head and Neck cancer in prostate, Lung, Colorectal, and Ovarian cancer Screening Trial Participants.
Lander DP; Kallogjeri D; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):249-256. PubMed ID: 38329760
[TBL] [Abstract] [Full Text] [Related]
9. Considerations from employed African-American and white prostate cancer survivors on prostate cancer treatment and survivorship: a qualitative analysis.
Owens OL; Dressler EV; Mayfield A; Winkfield KM; Krane LS; Foust M; Sandberg JC
Ethn Health; 2024 Apr; 29(3):309-327. PubMed ID: 38317577
[TBL] [Abstract] [Full Text] [Related]
10. Effects of Resilience and Emotion Regulation on Perceptions of Positive and Negative Life Changes in cancer Survivors: A Longitudinal Study.
Fritzson E; Bellizzi KM; Zhang N; Park CL
Ann Behav Med; 2024 Mar; 58(4):253-263. PubMed ID: 38309713
[TBL] [Abstract] [Full Text] [Related]
11. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
12. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
Westerberg M; Irenaeus S; Garmo H; Stattin P; Gedeborg R
PLoS One; 2024; 19(1):e0296804. PubMed ID: 38236934
[TBL] [Abstract] [Full Text] [Related]
13. Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
Pellegrino F; Stabile A; Sorce G; Mazzone E; Cannoletta D; Cirulli GO; Quarta L; Leni R; Robesti D; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2024 Apr; 84(5):473-478. PubMed ID: 38149793
[TBL] [Abstract] [Full Text] [Related]
14. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
15. Colorimetric and photothermal immunosensor for sensitive detection of cancer biomarkers based on enzyme-mediated growth of gold nanostars on polydopamine.
Gao Y; Wu Y; Huang P; Wu FY
Anal Chim Acta; 2023 Oct; 1279():341775. PubMed ID: 37827632
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.
Huang HP; Chen CH; Chang KH; Lee MS; Lee CF; Chao YH; Lu SY; Wu TF; Liang ST; Lin CY; Lin YC; Liu SP; Lu YC; Shun CT; Huang WJ; Lin TP; Ku MH; Chung HJ; Chang YH; Liao CH; Yu CC; Chung SD; Tsai YC; Wu CC; Chen KC; Ho CH; Hsiao PW; Pu YS
J Transl Med; 2023 Oct; 21(1):714. PubMed ID: 37821919
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of A Computer-Aided Detection Software for prostate cancer Prediction: Excellent Diagnostic Accuracy Independent of Preanalytical Factors.
Vazzano J; Johansson D; Hu K; Eurén K; Elfwing S; Parwani A; Zhou M
Lab Invest; 2023 Dec; 103(12):100257. PubMed ID: 37813279
[TBL] [Abstract] [Full Text] [Related]
18. The national utilization of nonoperative management for small renal masses over 10 years.
Filipas DK; Beatrici E; Nolazco JI; Qian Z; Marks P; Labban M; Stone BV; Pierorazio PM; Lipsitz SR; Trinh QD; Chang SL; Cole AP
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37802923
[TBL] [Abstract] [Full Text] [Related]
19. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in prostate cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of the Completeness of Managed Care Data to Identify cancer Diagnoses and Treatments for Patients in the SEER-Medicare Data.
Warren JL; Parsons HM; Mariotto AB; Boyd E; Enewold L
Med Care; 2023 Dec; 61(12):846-857. PubMed ID: 37796197
[TBL] [Abstract] [Full Text] [Related]
[Next]
